Annual Congress of the European Society for Medical Oncology
Bella Center #Copenhagen, DENMARK
The annual ESMO Congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for Congress attendees. Across disciplines and across cultures, ESMO bridges the gap between researchers, clinicians and patients and unites all stakeholders focused on finding the most effective cancer treatment solutions available today.
ESMO 2016 will continue to build upon the success of past Congresses, offering a top-notch scientific and educational programme created by international experts in oncology. We invite you to save the date now for ESMO 2016!
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Bella Center - Bella Center Copenhagen
5, Center Boulevard Copenhagen Denmark
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 11 May 2016 will be considered for late-breaking status. A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline. Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 23 August 2016, 21:00 CEST (Central European Summer Time)
The final late-breaking abstract deadline of 23 August 2016 is under no circumstances to be considered as an extension of the general submission deadline.
Trial in progress abstracts (TiP)
Trial in Progress abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO 2016.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections: Background and Trial design. Abstracts including results or preliminary data will be rejected.
Recruitment must have already begun or have been completed by the abstract submission deadline of 11 May 2016.
Encore TiP abstracts will NOT be accepted.
Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation.
The exhibition and Satellite Symposia are important components of the ESMO Congress, providing medical oncologists with an ideal platform to network with pharmaceutical partners and a dedicated opportunity to gain further insight into tangible advances in the treatment of cancer.
The major pharmaceutical companies active in the field of oncology are expected to take part in the Congress as exhibitors.
ESMO Contact Information
European Society for Medical Oncology (ESMO)
Via L. Taddei 4
Tel: +41 (0)91 973 19 00
Fax: +41 (0)91 973 19 02